This invention relates to humanized antibodies that selectively bind the 31.1 epitope on the A33 protein differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages.

The invention relates to a peptidomimetic of an NPC-1 epitope on the MUC5AC protein which is differentially expressed in pancreatic and colorectal cancer, and diagnostic and therapeutic usages. Further, antibodies that selectively bind the NPC-1 epitope peptidomimetics and may be used in diagnostic and therapeutic methods.

The invention relates to a peptidomimetic of an NPC-1 epitope on the MUC5AC protein which is differentially expressed in pancreatic and colorectal cancer, and diagnostic and therapeutic usages. Further, antibodies that selectively bind the NPC-1 epitope peptidomimetics and may be used in diagnostic and therapeutic methods.

The method for treating a cancer in a mammal in need thereof includes collecting a biological sample from said mammal; determining, from said biological sample, if the ADAMTSL5 gene is overexpressed; diagnosing a cancer from the determination of the overexpression of the gene; and administering to the mammal an effective amount of a pharmaceutical composition including an agent or agents targeting ADAMTSL5 or the ADAMTSL5 pathway, and a pharmaceutically acceptable carrier, where the composition comprises an inhibitor of ADAMTLS5 and is adapted to reducing overexpression of ADAMTSL5 in the mammal.

The method for treating a cancer in a mammal in need thereof includes collecting a biological sample from said mammal; determining, from said biological sample, if the ADAMTSL5 gene is overexpressed; diagnosing a cancer from the determination of the overexpression of the gene; and administering to the mammal an effective amount of a pharmaceutical composition including an agent or agents targeting ADAMTSL5 or the ADAMTSL5 pathway, and a pharmaceutically acceptable carrier, where the composition comprises an inhibitor of ADAMTLS5 and is adapted to reducing overexpression of ADAMTSL5 in the mammal.

The present invention relates to a method for analyzing a biological sample obtained from a subject, comprising analyzing components contained in a biological sample by an assay using a first molecule selected from the group consisting of a molecule binding to a sugar chain bindable with BC2LCN, a molecule binding to SerpinA3, and a molecule binding to Gal3BP, and a second molecule that is BC2LCN.